November 20, 2012
Due to Hurricane Sandy, APP Pharmaceuticals is facing unavoidable delays on inbound shipments and product releases of propofol, which has added additional impact to the shortage situation and is also creating some backorders.
APP has assured the FDA that they are committed to resolving the distribution challenges as quickly as possible. The FDA is working very closely with all manufacturers of propofol to assist with any regulatory actions needed to help increase supply of propofol in the market as soon as possible.
More information will be posted on the FDA's CDER drug shortage web site as soon as it becomes available.